Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism

Diabetes

Volumn 59, Issue 11, 2010, Pages 2862-2871

  Meagher, Craig ^a,b   Beilke, Josh ^c   Arreaza, Guillermo ^b   Mi, Qing Sheng ^b   Chen, Wei ^b   Salojin, Konstantin ^b   Horst, Noah ^c   Cruikshank, William W ^d   Delovitch, Terry L ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 16; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; CARBON TETRACHLORIDE; CD4-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; DIABETES MELLITUS, TYPE 1; HYPERINSULINISM; IMMUNOBLOTTING; INTERLEUKIN-16; ISLETS OF LANGERHANS; MICE; MICE, INBRED NOD; MICE, SCID; PANCREAS; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 78049233327     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-0131     Document Type: Article

References (49)

1. Bradley LM, Asensio VC, Schioetz LK, Harbertson J, Krahl T, Patstone G, Woolf N, Campbell IL, Sarvetnick N. Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J Immunol 1999;162:2511-2520
2. Kim SH, Cleary MM, Fox HS, Chantry D, Sarvetnick N. CCR4-bearing T cells participate in autoimmune diabetes. J Clin Invest 2002;110:1675-1686
3. Lohmann T, Laue S, Nietzschmann U, Kapellen TM, Lehmann I, Schroeder S, Paschke R, Kiess W. Reduced expression of Th1-associated chemokine receptors on peripheral blood lymphocytes at diagnosis of type 1 diabetes. Diabetes 2002;51:2474-2480
4. Lynch EA, Heijens CA, Horst NF, Center DM, Cruikshank WW. Cutting edge: IL-16/CD4 preferentially induces Th1 cell migration: requirement of CCR5. J Immunol 2003;171:4965-4968
5. Rahangdale S, Morgan R, Heijens C, Ryan TC, Yamasaki H, Bentley E, Sullivan E, Center DM, Cruikshank WW. Chemokine receptor CXCR3 desensitization by IL-16/CD4 signaling is dependent on CCR5 and intact membrane cholesterol. J Immunol 2006;176:2337-2345
6. Kurschner C, Yuzaki M. Neuronal interleukin-16 (NIL-16): a dual function PDZ domain protein. J Neurosci 1999;19:7770-7780
7. Cruikshank WW, Kornfeld H, Center DM. Interleukin-16. J Leukoc Biol 2000;67:757-766
8. Chupp GL, Wright EA, Wu D, Vallen-Mashikian M, Cruikshank WW, Center DM, Kornfeld H, Berman JS. Tissue and T cell distribution of precursor and mature IL-16. J Immunol 1998;161:3114-3119
9. Baier M, Bannert N, Werner A, Lang K, Kurth R. Molecular cloning, sequence, expression, and processing of the interleukin 16 precursor. Proc Natl Acad Sci U S A 1997;94:5273-5277
10. Zhang Y, Center DM, Wu DM, Cruikshank WW, Yuan J, Andrews DW, Kornfeld H. Processing and activation of pro-interleukin-16 by caspase-3. J Biol Chem 1998;273:1144-1149
11. Wu DM, Zhang Y, Parada NA, Kornfeld H, Nicoll J, Center DM, Cruikshank WW. Processing and release of IL-16 from CD4+ but not CD8+ T cells is activation dependent. J Immunol 1999;162:1287-1293
12. Cruikshank W, Center DM. Modulation of lymphocyte migration by human lymphokines. II. Purification of a lymphotactic factor (LCF). J Immunol 1982;128:2569-2574
13. Center DM, Cruikshank W. Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated mononuclear cells. J Immunol 1982;128:2563-2568
14. Cruikshank WW, Lim K, Theodore AC, Cook J, Fine G, Weller PF, Center DM. IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. J Immunol 1996;157:5240-5248
15. Mashikian MV, Ryan TC, Seman A, Brazer W, Center DM, Cruikshank WW. Reciprocal desensitization of CCR5 and CD4 is mediated by IL-16 and macrophage-inflammatory protein-1 beta, respectively. J Immunol 1999;163:3123-3130
16. Van Drenth C, Jenkins A, Ledwich L, Ryan TC, Mashikian MV, Brazer W, Center DM, Cruikshank WW. Desensitization of CXC chemokine receptor 4, mediated by IL-16/CD4, is independent of p56lck enzymatic activity. J Immunol 2000;165:6356-6363
17. Seegert D, Rosenstiel P, Pfahler H, Pfefferkorn P, Nikolaus S, Schreiber S. Increased expression of IL-16 in inflammatory bowel disease. Gut 2001;48:326-332 (Pubitemid 32269559)
18. Liang X, Ma L, Thai NL, Fung JJ, Qian S, Lu L. The role of liver-derived regulatory dendritic cells in prevention of type 1 diabetes. Immunology 2007;120:251-260
19. Kitchen SG, LaForge S, Patel VP, Kitchen CM, Miceli MC, Zack JA. Activation of CD8 T cells induces expression of CD4, which functions as a chemotactic receptor. Blood 2002;99:207-212
20. Bojunga J, Kusterer K, Bacher M, Kurek R, Usadel KH, Renneberg H. Macrophage migration inhibitory factor and development of type-1 diabetes in non-obese diabetic mice. Cytokine 2003;21:179-186
21. Matin K, Salam MA, Akhter J, Hanada N, Senpuku H. Role of stromal-cell derived factor-1 in the development of autoimmune diseases in non-obese diabetic mice. Immunology 2002;107:222-232
22. Cameron MJ, Arreaza GA, Grattan M, Meagher C, Sharif S, Burdick MD, Strieter RM, Cook DN, Delovitch TL. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. J Immunol 2000;165:1102-1110
23. Christen U, McGavern DB, Luster AD, von Herrath MG, Oldstone MB. Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. J Immunol 2003;171:6838-6845
24. Frigerio S, Junt T, Lu B, Gerard C, Zumsteg U, Holländer GA, Piali L. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med 2002;8:1414-1420
25. Höglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med 1999;189:331-339
26. Cameron MJ, Arreaza GA, Zucker P, Chensue SW, Strieter RM, Chakrabarti S, Delovitch TL. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J Immunol 1997;159:4686-4692
27. Meagher C, Arreaza G, Peters A, Strathdee CA, Gilbert PA, Mi QS, Santamaria P, Dekaban GA, Delovitch TL. CCL4 protects from type 1 diabetes by altering islet beta-cell-targeted inflammatory responses. Diabetes 2007;56:809-817
28. Sobel DO, Han J, Williams J, Yoon JW, Jun HS, Ahvazi B. Gamma interferon paradoxically inhibits the development of diabetes in the NOD mouse. J Autoimmun 2002;19:129-137
29. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, Eisenbarth GS, Mathis D, Rossini AA, Campbell SE, Kahn R, Kreuwel HT. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005;23:115-126
30. Skundric DS, Cai J, Cruikshank WW, Gveric D. Production of IL-16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions. J Neuroinflammation 2006;3:13
31. Skundric DS, Dai R, Zakarian VL, Bessert D, Skoff RP, Cruikshank WW, Kurjakovic Z. Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE. J Neurosci Res 2005;79:680-693
32. Wang S, Diao H, Guan Q, Cruikshank WW, Delovitch TL, Jevnikar AM, Du C. Decreased renal ischemia-reperfusion injury by IL-16 inactivation. Kidney Int 2008;73:318-326
33. Hutchings P, O'Reilly L, Parish NM, Waldmann H, Cooke A. The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to beta cells in NOD mice. Eur J Immunol 1992;22:1913-1918
34. Liu E, Moriyama H, Paronen J, Abiru N, Miao D, Yu L, Taylor RM, Eisenbarth GS. Nondepleting anti-CD4 monoclonal antibody prevents diabetes and blocks induction of insulin autoantibodies following insulin peptide B:9-23 immunization in the NOD mouse. J Autoimmun 2003;21:213-219
35. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998;280:243-248
36. Chervonsky AV. Apoptotic and effector pathways in autoimmunity. Curr Opin Immunol 1999;11:684-688
37. Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter EH, Cyopick P, Danska JS, Delovitch TL. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993;178:87-99
38. Decallonne B, van Etten E, Giulietti A, Casteels K, Overbergh L, Bouillon R, Mathieu C. Defect in activation-induced cell death in non-obese diabetic (NOD) T lymphocytes. J Autoimmun 2003;20:219-226
39. Salojin KV, Zhang J, Madrenas J, Delovitch TL. T-cell anergy and altered T-cell receptor signaling: effects on autoimmune disease. Immunol Today 1998;19:468-473
40. Arreaza G, Salojin K, Yang W, Zhang J, Gill B, Mi QS, Gao JX, Meagher C, Cameron M, Delovitch TL. Deficient activation and resistance to activation-induced apoptosis of CD8+ T cells is associated with defective peripheral tolerance in nonobese diabetic mice. Clin Immunol 2003;107:103-115
41. Noorchashm H, Moore DJ, Noto LE, Noorchashm N, Reed AJ, Reed AL, Song HK, Mozaffari R, Jevnikar AM, Barker CF, Naji A. Impaired CD4 T cell activation due to reliance upon B cell-mediated costimulation in nonobese diabetic (NOD) mice. J Immunol 2000;165:4685-4696
42. Liu Y, Janeway CA Jr. Interferon gamma plays a critical role in induced cell death of effector T cell: a possible third mechanism of self-tolerance. J Exp Med 1990;172:1735-1739
43. Dalton DK, Haynes L, Chu CQ, Swain SL, Wittmer S. Interferon gamma eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J Exp Med 2000;192:117-122
44. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med 2002;196:999-1005
45. Bergerot I, Arreaza GA, Cameron MJ, Burdick MD, Strieter RM, Chensue SW, Chakrabarti S, Delovitch TL. Insulin B-chain reactive CD4+ regulatory T-cells induced by oral insulin treatment protect from type 1 diabetes by blocking the cytokine secretion and pancreatic infiltration of diabetogenic effector T-cells. Diabetes 1999;48:1720-1729
46. Pfleger C, Kaas A, Hansen L, Alizadeh B, Hougaard P, Holl R, Kolb H, Roep BO, Mortensen HB, Schloot NC, Hvidøre Study Group On Childhood Diabetes. Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes. Clin Immunol 2008;128:57-65
47. Staudinger R, Phogat SK, Xiao X, Wang X, Dimitrov DS, Zolla-Pazner S. Evidence for CD4-enchanced signaling through the chemokine receptor CCR5. J Biol Chem 2003;278:10389-10392
48. Seifarth C, Mack M, Steinlicht S, Hahn EG, Lohmann T. Transient chemokine receptor blockade does not prevent, but may accelerate type 1 diabetes in prediabetic NOD mice. Horm Metab Res 2006;38:167-171
49. Solomon M, Balasa B, Sarvetnick N. CCR2 and CCR5 chemokine receptors differentially influence the development of autoimmune diabetes in the NOD mouse. Autoimmunity 2010;43:156-163